GAL and allergic disease: Dinutuximab is expressed by traditional Sp2/0 cells and contains a Gal-α3Gal glycosylation-modified epitope, which may induce allergy, while the improved version (Ch14.18, named dinutuximab β) expressed in CHO cells had a better glycosylation pattern compared to dinutuximab and avoided virus contamination from mice since it contains almost no Gal-α3Gal; dinutuximab β was approved by the European Medicines Agency (EMA) for high-risk neuroblastoma in 2017.123